These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 31833462)

  • 1. Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.
    Reinecke BA; Wang H; Zhang Y
    Curr Top Med Chem; 2019; 19(26):2378-2392. PubMed ID: 31833462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors.
    Mohr K; Schmitz J; Schrage R; Tränkle C; Holzgrabe U
    Angew Chem Int Ed Engl; 2013 Jan; 52(2):508-16. PubMed ID: 23225228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry.
    Fronik P; Gaiser BI; Sejer Pedersen D
    J Med Chem; 2017 May; 60(10):4126-4134. PubMed ID: 28140580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs.
    Valant C; Sexton PM; Christopoulos A
    Mol Interv; 2009 Jun; 9(3):125-35. PubMed ID: 19592673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bridging the gap: bitopic ligands of G-protein-coupled receptors.
    Lane JR; Sexton PM; Christopoulos A
    Trends Pharmacol Sci; 2013 Jan; 34(1):59-66. PubMed ID: 23177916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled Receptors.
    Feng Z; Hu G; Ma S; Xie XQ
    AAPS J; 2015 Sep; 17(5):1080-95. PubMed ID: 25940084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational design of dualsteric GPCR ligands: quests and promise.
    Mohr K; Tränkle C; Kostenis E; Barocelli E; De Amici M; Holzgrabe U
    Br J Pharmacol; 2010 Mar; 159(5):997-1008. PubMed ID: 20136835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity.
    Antony J; Kellershohn K; Mohr-Andrä M; Kebig A; Prilla S; Muth M; Heller E; Disingrini T; Dallanoce C; Bertoni S; Schrobang J; Tränkle C; Kostenis E; Christopoulos A; Höltje HD; Barocelli E; De Amici M; Holzgrabe U; Mohr K
    FASEB J; 2009 Feb; 23(2):442-50. PubMed ID: 18842964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors.
    Valant C; Robert Lane J; Sexton PM; Christopoulos A
    Annu Rev Pharmacol Toxicol; 2012; 52():153-78. PubMed ID: 21910627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric modulators of G-protein-coupled receptors.
    May LT; Christopoulos A
    Curr Opin Pharmacol; 2003 Oct; 3(5):551-6. PubMed ID: 14559102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of allosteric modulators of GPCRs for treatment of CNS disorders.
    Nickols HH; Conn PJ
    Neurobiol Dis; 2014 Jan; 61():55-71. PubMed ID: 24076101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.
    Valant C; Gregory KJ; Hall NE; Scammells PJ; Lew MJ; Sexton PM; Christopoulos A
    J Biol Chem; 2008 Oct; 283(43):29312-21. PubMed ID: 18723515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When simple agonism is not enough: emerging modalities of GPCR ligands.
    Smith NJ; Bennett KA; Milligan G
    Mol Cell Endocrinol; 2011 Jan; 331(2):241-7. PubMed ID: 20654693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.
    Keov P; Sexton PM; Christopoulos A
    Neuropharmacology; 2011 Jan; 60(1):24-35. PubMed ID: 20637785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.
    Gado F; Ferrisi R; Polini B; Mohamed KA; Ricardi C; Lucarini E; Carpi S; Domenichini F; Stevenson LA; Rapposelli S; Saccomanni G; Nieri P; Ortore G; Pertwee RG; Ghelardini C; Di Cesare Mannelli L; Chiellini G; Laprairie RB; Manera C
    J Med Chem; 2022 Jul; 65(14):9918-9938. PubMed ID: 35849804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric modulators targeting CNS muscarinic receptors.
    Bock A; Schrage R; Mohr K
    Neuropharmacology; 2018 Jul; 136(Pt C):427-437. PubMed ID: 28935216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric modulation of G protein-coupled receptors.
    May LT; Avlani VA; Sexton PM; Christopoulos A
    Curr Pharm Des; 2004; 10(17):2003-13. PubMed ID: 15279541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing drugs and chemical probes with the dualsteric approach.
    Zha J; He J; Wu C; Zhang M; Liu X; Zhang J
    Chem Soc Rev; 2023 Dec; 52(24):8651-8677. PubMed ID: 37990599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery.
    Zhang M; Chen T; Lu X; Lan X; Chen Z; Lu S
    Signal Transduct Target Ther; 2024 Apr; 9(1):88. PubMed ID: 38594257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis for Allosteric Modulation of Class B G Protein-Coupled Receptors.
    Wootten D; Miller LJ
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():89-107. PubMed ID: 31454292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.